AU2002337442A1 - Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia - Google Patents

Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia

Info

Publication number
AU2002337442A1
AU2002337442A1 AU2002337442A AU2002337442A AU2002337442A1 AU 2002337442 A1 AU2002337442 A1 AU 2002337442A1 AU 2002337442 A AU2002337442 A AU 2002337442A AU 2002337442 A AU2002337442 A AU 2002337442A AU 2002337442 A1 AU2002337442 A1 AU 2002337442A1
Authority
AU
Australia
Prior art keywords
lymphoma
leukemia
diagnosis
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002337442A
Inventor
Javier Martin Hernandez
Helle Moving
Anne Ahlmann Nielsen
Finn Skou Pedersen
Annette Balle Sorensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aarhus Universitet
Original Assignee
Aarhus Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/962,854 external-priority patent/US20030044803A1/en
Priority claimed from US09/962,855 external-priority patent/US20020164576A1/en
Priority claimed from US09/962,929 external-priority patent/US20020115058A1/en
Priority claimed from US09/963,131 external-priority patent/US20030224460A1/en
Application filed by Aarhus Universitet filed Critical Aarhus Universitet
Publication of AU2002337442A1 publication Critical patent/AU2002337442A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002337442A 2001-09-24 2002-09-24 Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia Abandoned AU2002337442A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US09/962,916 2001-09-24
US09/962,854 US20030044803A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of JAK1
US09/962,854 2001-09-24
US09/962,855 US20020164576A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2
US09/962,929 US20020115058A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of Pik3r1
US09/963,131 US20030224460A1 (en) 2000-09-22 2001-09-24 Novel compositions and methods for lymphoma and leukemia
US09/963,131 2001-09-24
US09/962,855 2001-09-24
US09/962,929 2001-09-24
US09/962,916 US20030077590A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
PCT/IB2002/004134 WO2003027276A2 (en) 2001-09-24 2002-09-24 Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia

Publications (1)

Publication Number Publication Date
AU2002337442A1 true AU2002337442A1 (en) 2003-04-07

Family

ID=27542309

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2002364889A Abandoned AU2002364889A1 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of nrf2
AU2002337442A Abandoned AU2002337442A1 (en) 2001-09-24 2002-09-24 Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia
AU2002330713A Abandoned AU2002330713A1 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
AU2002329000A Abandoned AU2002329000A1 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2002364889A Abandoned AU2002364889A1 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of nrf2

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2002330713A Abandoned AU2002330713A1 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
AU2002329000A Abandoned AU2002329000A1 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1

Country Status (2)

Country Link
AU (4) AU2002364889A1 (en)
WO (5) WO2003027321A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1959969A2 (en) * 2005-07-01 2008-08-27 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
KR20090019767A (en) * 2006-02-14 2009-02-25 더프레지던트앤드펠로우즈오브하바드칼리지 Mitotic progression genes and methods of modulating mitosis

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ237669A (en) * 1990-04-13 1992-08-26 Res Dev Foundation T-cell proteins expressed in t-cell development and their preparation
US5821069A (en) * 1993-06-30 1998-10-13 Ludwig Institute For Cancer Research Method for determining tyrosine kinase in a sample
US6300058B1 (en) * 1992-01-29 2001-10-09 Hitachi Chemical Research Center, Inc. Method for measuring messenger RNA
WO1997003358A1 (en) * 1995-07-07 1997-01-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of identifying inhibitors of the jak-stat signal transduction pathway
WO1998016557A1 (en) * 1996-10-11 1998-04-23 The General Hospital Corporation Assays for g-protein-linked receptors
JP2000506396A (en) * 1996-11-01 2000-05-30 オニックス ファーマシューティカルズ，インコーポレイティド Nucleotide sequence encoding phosphatidylinositol-3'-kinase-related protein and use thereof
AU742342B2 (en) * 1997-05-21 2001-12-20 Clontech Laboratories, Inc. Nucleic acid arrays
US5994076A (en) * 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
WO1999038972A2 (en) * 1998-01-28 1999-08-05 Chiron Corporation Human genes and gene expression products ii
EP1063887A1 (en) * 1998-02-23 2001-01-03 Quark Biotech, Inc. P53-dependent secretion of growth inhibitory factors
DE19817947A1 (en) * 1998-04-17 1999-10-28 Metagen Gesellschaft Fuer Genomforschung Mbh New nucleic acid sequences expressed in uterine myoma, and derived polypeptides, for treatment of uterine carcinoma and identification of therapeutic agents
IL139080A0 (en) * 1998-04-17 2001-11-25 Parker Hughes Inst Btx inhibitors and methods for their indentification and use
WO1999065928A2 (en) * 1998-06-19 1999-12-23 Genzyme Corporation Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues
US6100090A (en) * 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
JP2002536963A (en) * 1998-12-22 2002-11-05 ミリアド・ジェネティックス・インコーポレイテッド Protein-protein interaction in neurodegenerative diseases
US6110664A (en) * 1999-06-25 2000-08-29 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-S1 expression
GB9917165D0 (en) * 1999-07-22 1999-09-22 Knoll Ag Polypeptides polynuclcotides and uses thereof
ATE309241T1 (en) * 1999-09-10 2005-11-15 Merck & Co Inc TYROSINE KINASE INHIBITORS
CA2389834A1 (en) * 1999-10-25 2001-05-03 Monica Mody Genetic sequences associated with neural cell proliferation and disease
AU1760201A (en) * 1999-11-12 2001-06-06 Fred Hutchinson Cancer Research Center Methods for treatment of human huntington's disease and methods of screening foractive agents
WO2001051670A2 (en) * 2000-01-07 2001-07-19 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
GB2375172A (en) * 2000-02-07 2002-11-06 Quark Biotech Inc Fas pathway genes
DE60144277D1 (en) * 2000-04-25 2011-05-05 Icos Corp HEMMER OF HUMAN PHOSPHATIDYL-INOSITOL-3-KINASE DELTA
KR100830859B1 (en) * 2000-04-27 2008-05-21 아스텔라스세이야쿠 가부시키가이샤 Imidazopyridine derivatives and pharmaceutical composition comprising the same
WO2001096390A2 (en) * 2000-06-09 2001-12-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US6794137B2 (en) * 2000-09-08 2004-09-21 New York University Gene markers useful for detecting skin damage in response to ultraviolet radiation
JP2004527218A (en) * 2000-09-08 2004-09-09 ニューヨーク・ユニバーシティ Genetic markers useful for detecting UV-responsive skin damage
EP1362122A2 (en) * 2000-09-12 2003-11-19 TransGenetics Incorporated Microarrayed organization of transcription factor target genes
AU2001290965A1 (en) * 2000-09-13 2002-03-26 Archemix Corporation Target activated nucleic acid biosensor and methods of using same
WO2002040637A2 (en) * 2000-11-20 2002-05-23 Isis Pharmaceuticals, Inc. Antisense modulation of pi3k p85 expression
WO2002059367A2 (en) * 2000-11-30 2002-08-01 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Diagnostic microarray for inflammatory bowel disease, crohn's disease and ulcerative colitis
CA2436487A1 (en) * 2001-01-30 2002-08-08 Cytopia Pty Ltd. Methods of inhibiting kinases
AUPR279101A0 (en) * 2001-01-30 2001-02-22 Cytopia Pty Ltd Protein kinase signalling
US20020137086A1 (en) * 2001-03-01 2002-09-26 Alexander Olek Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylation status of the genes
AU2002330039A1 (en) * 2001-09-17 2003-04-01 Eos Biotechnology, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
GB0122914D0 (en) * 2001-09-22 2001-11-14 Univ Nottingham Modulation of stat activity

Also Published As

Publication number Publication date
WO2003027320A3 (en) 2003-10-23
AU2002364889A1 (en) 2003-06-10
WO2003027295A2 (en) 2003-04-03
AU2002330713A1 (en) 2003-04-07
WO2003027321A3 (en) 2003-11-06
WO2003043565A3 (en) 2003-11-13
WO2003027276A2 (en) 2003-04-03
AU2002364889A8 (en) 2003-06-10
WO2003027321A2 (en) 2003-04-03
WO2003043565A2 (en) 2003-05-30
WO2003027320A2 (en) 2003-04-03
WO2003027276A3 (en) 2004-02-12
WO2003027295A3 (en) 2003-10-16
AU2002329000A1 (en) 2003-04-07

Similar Documents

Publication Publication Date Title
AU2002332020A1 (en) Compositions for oral gene therapy and methods of using same
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
WO2003008583A3 (en) Novel compositions and methods for cancer
AU2002257936A1 (en) Methods of well treatment
AU2002225219A1 (en) Diagnosis and treatment of multiple sclerosis
AU2002243023A1 (en) Compositions for preventing and/or treating oral diseases
AU2001233081A1 (en) Composition for treatment of stress
AU2002352533A1 (en) Methods and compositions for treatment of gastric diseases
AU2002362098A1 (en) Methods of therapy for non-hodgkin's lymphoma
AU2002361149A1 (en) Set of teeth
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
AU2002364708A1 (en) Novel compositions and methods for cancer
AU2002302570A1 (en) Hair treatment compositions
WO2003053224A3 (en) Novel compositions and methods for cancer
PL368035A1 (en) Compositions and methods for the treatment of cancer
AU2003219160A1 (en) Methods and compositions for the treatment of cancer
WO2002024867A3 (en) Novel compositions and methods for lymphoma and leukemia
AU2002346882A1 (en) Methods for the treatment of osteoarthritis and compositions thereof
AU2002337943A1 (en) Novel compositions and methods for cancer
AU2002342865A1 (en) Hair treatment compositions
AU2002337442A1 (en) Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia
AU2002363228A1 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
AUPR644301A0 (en) Method and composition for treatment of cancer
AU2003240174A1 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
AU2002322862A1 (en) Methods and compositions for diagnosis and treatment of vascular conditions

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase